$12.15−0.31 (−2.49%)
At close: Nov 19, 2026, 4:00 PM ET· Nasdaq · USD
SkinHealth Systems (SKIN) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Sources Company filings FilingsHow we compute thisNot investment advice
Business engineChoppy: revenue fell 10.0% in FY25, net margin −3.2%. Worth your attention in FY25: Share count (+33.0%). Visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)▼10.0%
300.8
FY21→FY25CAGR +3.7%/yr
Net income ($M)▲67.3%
−9.5
one-off year: see footnoteCAGR —
Free cash flow ($M)▲141.8%
37.2
FY21→FY25CAGR —
Diluted EPS▲55.6%
−0.16
no value for 1 of 5 yearsCAGR —
What the receipts whisper · what a headline number hides
Share count
+33.0%
102.1mn → 135.8mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.
Capex
$303.0K
−59.9% YoY in FY25 · 0.1% of revenue.
What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)
-3¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.
Margin trend · direction beats level Gross Operating Net
Over this window: gross 68.6% → 65.3%. Net margin -3.2% is more than double the sector median.
The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
The annual and quarterly statements are struck on share counts that differ by a factor of 20.86, so per-share figures cannot be compared across the two tables. Each table's per-share figures are on its own share basis. On the latest annual statement the reported earnings per share does not reconcile with net income to common shareholders divided by the reported share count (a factor of 2.283), so the two figures are on different bases. Both are shown as filed.
USD thousands except per-share & ratios
| Line item | TTM † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | 288,562.0 | 300,790.0 | 334,294.0 | 397,991.0 | 365,876.0 | 260,086.0 | ▼10.0% | +3.7% |
Cost of revenue | 94,600.0 | 104,426.0 | 151,998.0 | 242,878.0 | 117,097.0 | 81,548.0 | ▼31.3% | +6.4% |
Gross profit | 193,962.0 | 196,364.0 | 182,296.0 | 155,113.0 | 248,779.0 | 178,538.0 | ▲7.7% | +2.4% |
Research & development | 5,852.0 | 5,628.0 | 6,296.0 | 10,102.0 | 8,444.0 | 8,195.0 | ▼10.6% | −9.0% |
Selling, general & admin | 93,465.0 | 117,949.0 | 125,463.0 | 131,432.0 | 106,100.0 | 98,688.0 | ▼6.0% | +4.6% |
Total operating expenses | 187,051.0 | 217,167.0 | 250,070.0 | 286,030.0 | 274,620.0 | 218,466.0 | ▼13.2% | −0.1% |
Operating incomefeeds ROC rank | 6,911.0 | −20,803.0 | −67,774.0 | −130,917.0 | −25,841.0 | −39,928.0 | ▲69.3% | — |
Other income, net | −20,102.0 | 14,865.0 | 38,224.0 | 29,028.0 | 71,180.0 | −340,711.0 | — | — |
Pretax income | −13,191.0 | −5,938.0 | −29,550.0 | −101,889.0 | 45,339.0 | −380,639.0 | ▲79.9% | — |
Income tax | 5,100.0 | 3,581.0 | −452.0 | −1,773.0 | 1,115.0 | −1,875.0 | — | +47.5% (22→25) |
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings | −18,291.0 | −9,519.0 | −29,098.0 | −100,116.0 | 44,224.0 | −378,764.0 | ▲67.3% | — |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | — | −0.16 | −0.36 | −0.76 | — | −3.67 | ▲55.6% | — |
Diluted shares (mn) | — | 135.80 | 142.49 | 131.68 | — | 102.11 | ▼4.7% | — |
| Margins | ||||||||
Gross margin44th pct in Healthcare | 67.2% | 65.3% | 54.5% | 39.0% | 68.0% | 68.6% | ▲10.8pp | −3.4pp |
Operating margin | 2.4% | −6.9% | −20.3% | −32.9% | −7.1% | −15.4% | ▲13.4pp | +8.4pp |
Net margin52nd pct in Healthcare | −6.3% | −3.2% | −8.7% | −25.2% | 12.1% | −145.6% | ▲5.5pp | +142.5pp |
† TTM = trailing four quarters through 2026-09-30.FY25 effective tax rate was −60% vs a 2% norm for this window, likely a one-time item; see the filing.
3 more years of statements and CSV export are on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-03-12 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Common questions
What was SkinHealth Systems' revenue last fiscal year?
SkinHealth Systems reported revenue of $300.8M in fiscal 2025, down 10.0% from fiscal 2024.
What was SkinHealth Systems' net income?
SkinHealth Systems reported net income of −$9.5M in fiscal 2025, a net margin of −3.2%.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

